Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

To Study and Explore the Predictive Effect of Insulin Resistance-related Indicators on In-stent Restenosis After Coronary Stent Implantation

22. maj 2026 opdateret af: Qilu Hospital of Shandong University

The Predictive Effect of Insulin Resistance Metabolic Score on In-stent Restenosis After Coronary Stent Implantation

Based on previous studies on insulin resistance and cardiovascular diseases, we believe that the insulin resistance metabolic score also has certain predictive value for the prognosis of in-stent restenosis after coronary stent implantation. The main purpose of this study is to explore the predictive effect of the insulin resistance metabolic score on in-stent restenosis after coronary stent implantation and to discuss a reasonable control level.

Studieoversigt

Status

Afsluttet

Betingelser

Intervention / Behandling

Detaljeret beskrivelse

Coronary atherosclerotic heart disease, especially acute myocardial infarction, remains the leading cause of death worldwide. Despite the development and improvement of percutaneous coronary intervention (PCI) and drug therapy, which have significantly improved survival rates and clinical outcomes, the unresolved problem of in-stent restenosis (ISR) remains a key factor limiting the therapeutic effect. Therefore, identifying and studying the risk factors and formation mechanisms of in-stent restenosis is an important clinical step in preventing and treating in-stent restenosis. Moreover, an increasing number of studies have shown that IR may have a significant impact on the occurrence and progression of in-stent restenosis (ISR). The traditional quantitative techniques for assessing IR are limited by cost, time, and manpower, while new biomarkers overcome these limitations and become a clinically feasible alternative with cardiovascular disease prediction capabilities. However, there is currently no large amount of data to prove the relationship between metabolic syndrome-insulin resistance (METS-IR) and in-stent restenosis (ISR). Therefore, we designed a retrospective study on patients with recurrent chest pain after percutaneous coronary intervention to evaluate the potential association between subepithelial restenosis (ISR) and metabolic syndrome-insulin resistance (METS-IR), thereby providing a basis for evaluating METS-IR as a possible risk indicator for ISR in patients after percutaneous coronary intervention.

Undersøgelsestype

Observationel

Tilmelding (Faktiske)

1000

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiesteder

  • Kina
    • Shandong
      • Jinan, Shandong, Kina, 250012
        • Qilu Hospital of Shandong University

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

  • Voksen
  • Ældre voksen

Tager imod sunde frivillige

Ingen

Prøveudtagningsmetode

Ikke-sandsynlighedsprøve

Studiebefolkning

We retrospectively collected the clinical data of patients with recurrent chest pain after PCI and requiring repeated angiography from January 2022 to November 2025, which were obtained from electronic medical records.

Beskrivelse

Inclusion Criteria:

  • Age ≥45 years
  • Patients with a history of percutaneous coronary intervention (PCI) with stent implantation
  • Patients who underwent repeat coronary angiography during follow-up
  • Complete clinical data available, including echocardiography, 24-hour ambulatory electrocardiogram, NT-proBNP, liver and kidney function tests, and blood biochemical tests

Exclusion Criteria:

  • Previous coronary artery bypass grafting
  • Lesions treated only with balloon angioplasty without stent implantation
  • Clinical manifestations of heart failure, structural cardiomyopathy, congenital heart disease, or significant valvular heart disease
  • Severe hepatic or renal dysfunction, such as estimated glomerular filtration rate <30 mL/min/1.73 m²
  • Incomplete clinical or angiographic data

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Incidence of in-stent restenosis greater than 50% and greater than 70% assessed by follow-up coronary angiography
Tidsramme: During follow-up coronary angiography within 6-60 months after PCI
In-stent restenosis was defined as recurrent luminal diameter stenosis within the stented segment or within 5 mm proximal or distal to the stent edges, as determined by follow-up coronary angiography. Percent diameter stenosis was used to quantify the severity of restenosis. Participants will be classified according to whether they had in-stent restenosis greater than 50% and greater than 70%, and the outcome will be summarized as the number and percentage of participants in each category.
During follow-up coronary angiography within 6-60 months after PCI

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Sponsor

Qilu Hospital of Shandong University

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Faktiske)

1. januar 2022

Primær færdiggørelse (Faktiske)

1. november 2025

Studieafslutning (Faktiske)

1. november 2025

Datoer for studieregistrering

Først indsendt

6. februar 2026

Først indsendt, der opfyldte QC-kriterier

22. maj 2026

Først opslået (Faktiske)

29. maj 2026

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

29. maj 2026

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

22. maj 2026

Sidst verificeret

1. januar 2026

Mere information

Begreber relateret til denne undersøgelse

Yderligere relevante MeSH-vilkår

Andre undersøgelses-id-numre

  • KYLL-2025-11-064

Plan for individuelle deltagerdata (IPD)

Planlægger du at dele individuelle deltagerdata (IPD)?

UBESLUTET

Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter

Studerer et amerikansk FDA-reguleret lægemiddelprodukt

Ingen

Studerer et amerikansk FDA-reguleret enhedsprodukt

Ingen

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .

Kliniske forsøg med Koronararteriesygdom

Søg i lignende forsøg

Sponsorer og samarbejdspartnere

Medicinske tilstande

Narkotikainterventioner

CROs by country

CROs in El Salvador

Betingelser

Sjældne sygdomme

Narkotikainterventioner

Kosttilskud

Sponsor / samarbejdspartnere

Placeringer

Abonner